Pascal Girin – CEO, BALT, France
Pascal Girin, CEO of BALT, shares how his rich career in neurovascular medical technology helped him to transform the company from a small R&D pure player into an international market…
Alfa Wassermann is a pharmaceutical group with an Italian heart and an international outlook. For over sixty years, it has researched, manufactured and distributed drugs of primary importance for human health, allowing people to benefit from new discoveries in medicine, biology and genomics. Today the Group operates in 12 different countries and employs approximately 1,370 employees, 670 of which in Italy.
Alfa Wassermann´s strategy is to focus on the gastro-intestinal area. Already present in IBS, constipation and diarrhoea, with the launch of Rifaximin-alpha 500 they will be active in a further major gastro-intestinal related area, namely hepatic encephalopathy. In France market authorization was received for Rifaximin-alpha 500mg in January 2015. Alfa Wassermann and its partner Norgine will jointly promote and manage the clinical development of Rifaximine alpha 550 mg in France.
Contact
ALFA WASSERMANN PHARMA SAS
67, rue Anatole France
92300 Levallois Perret – France
Ph. +33 1 41 27 25 10 – Fax +33 1 47 58 77 04
Pascal Girin, CEO of BALT, shares how his rich career in neurovascular medical technology helped him to transform the company from a small R&D pure player into an international market…
Pascal Brière, president of Biogaran, the leading French domestic player in generics, reflects on the development of the generic market since the 1999 Generic Substitution Act. Brière goes on to…
Bertrand Sohier, VP and general manager business and administration of Parexel France discusses the latest trends impacting the clinical research environment of the country, gives insight on the strategies the…
Michel Spagnol, chairman and CEO of Novasep, a robust French CDMO, shares his insights on the key global trends that are shaping today’s CMDO sector – particularly the emerging significance…
France is rediscovering its mojo. After a period of relative stagnation, the country’s highly strategic USD 65 billion healthcare and life sciences market is once again an attractive investment proposition.…
Jean-Marc Grognet, general manager of Genopole, France’s leading biotechnology cluster, explains the organization’s unique triangular structure with the corner points of the cluster being higher education, research, and industry. Grognet…
Jean-Louis Anspach, general manager of Teva France, elaborates on the affiliate’s transitional restructuring period as they make a turnaround effort in the face of group-wide challenges. Anspach goes on to…
Patrick Mahieux, general manager of ABL Europe, a CDMO specialized in the provision of viral vectors, discusses the company’s history within the Institut Mérieux and, the unique and flexible strategy…
Jaques Chevallet, CEO of Arkopharma, a European leader in herbal medicines and dietary supplements, discusses the company’s development over recent years while sharing his assessment on the current condition of…
Elizabeth Ducottet, the 5th generation CEO of French family company Thuasne, shares the group’s history and goes on to explain how it has evolved into a professionally and innovatively driven…
Marc Oczachowski, CEO of EDAP TMS, a French medtech and global leader in therapeutic ultrasound, elaborates on the history of the company while discussing their newest innovation for the noninvasive…
In an exclusive interview, Dominique Le Guludec, president of the French National Authority for Health (Haute Autorité de Santé (HAS)), offers her insider comments on the changes in French healthcare…
See our Cookie Privacy Policy Here
